Cyteir Therapeutics is a biotechnology business based in the US. Cyteir Therapeutics shares (CYT) are listed on the NASDAQ and all prices are listed in US Dollars. Cyteir Therapeutics employs 46 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $3.02 |
|---|---|
| 52-week range | $2.75 - $3.19 |
| 50-day moving average | $3.08 |
| 200-day moving average | $2.93 |
| Wall St. target price | $3.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.93 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.02 from 2024-03-15
| 1 week (2024-08-26) | N/A |
|---|---|
| 1 month (2024-08-02) | N/A |
| 3 months (2024-06-02) | N/A |
| 6 months (2024-03-06) | -0.98% |
| 1 year (2023-09-06) | 8.63% |
|---|---|
| 2 years (2022-09-06) | 43.81% |
| 3 years (2021-09-03) | 20.53 |
| 5 years (2019-09-02) | N/A |
| Gross profit TTM | $-16,591,000 |
|---|---|
| Return on assets TTM | -14.5% |
| Return on equity TTM | -23.81% |
| Profit margin | 0% |
| Book value | $3.47 |
| Market Capitalization | $108.7 million |
TTM: trailing 12 months
We're not expecting Cyteir Therapeutics to pay a dividend over the next 12 months.
Cyteir Therapeutics's shares were split on a 2:1 basis on 17 September 2014. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Cyteir Therapeutics shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Cyteir Therapeutics shares which in turn could have impacted Cyteir Therapeutics's share price.
Over the last 12 months, Cyteir Therapeutics's shares have ranged in value from as little as $2.75 up to $3.19. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cyteir Therapeutics's is 0.096. This would suggest that Cyteir Therapeutics's shares are less volatile than average (for this exchange).
To put Cyteir Therapeutics's beta into context you can compare it against those of similar companies.
Cyteir Therapeutics, Inc. , a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts. .
Use this calculator to quickly see potential outcomes of your options trades.
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.